Table 2 Patient characteristics för SSc-ILD prospective group
Characteristic | Anti-Ro52 negative, N = 33 (77%)a | Anti-Ro52 positive, N = 10 (23%)a | Overall, N = 43a | p-valueb |
|---|---|---|---|---|
Female | 26 (79%) | 9 (90%) | 35 (81%) | 0.656 |
Weight (kg) | 70.8 (15.0) | 61.0 (6.5) | 68.5 (14.1) | 0.029 |
Height (m) | 1.68 (0.9) | 1.63 (0.6) | 1.67 (0.09) | 0.185 |
Smokingc | 12 (38%) | 2 (20%) | 14 (33%) | 0.451 |
dcSSc | 13 (39%) | 3 (30%) | 16 (37%) | 0.719 |
Myositis | 2 (6.1%) | 2 (20%) | 4 (9.3%) | 0.226 |
PAH | 3 (9.1%) | 1 (10%) | 4 (9.3%) | > 0.999 |
Autoantibodies | ||||
Anti-Scl-70 | 13 (39%) | 3 (30%) | 16 (37%) | 0.719 |
Anti-centromere | 5 (15%) | 1 (10%) | 6 (14%) | > 0.999 |
Anti-RNA polymerase III | 5 (15%) | 2 (20%) | 7 (16%) | 0.656 |
ANA patternd | ||||
Homogeneous (AC-1) | 12 (37%) | 4 (40%) | 16 (37%) | > 0.999 |
Centromere (AC-3) | 4 (12%) | 1 (10%) | 5 (12%) | > 0.999 |
Large speckled (AC-5) | 14 (42%) | 8 (80%) | 22 (51%) | 0.069 |
Nucleolar (AC-8/9/10) | 8 (24%) | 2 (20%) | 10 (23%) | > 0.999 |
Immunomodulator usee | 30 (91%) | 8 (80%) | 38 (88%) | 0.575 |
Baseline vital capacity (liters) | 3.1 (0.8) | 2.7 (0.6) | 3.0 (0.8) | 0.342 |
Baseline vital capacity (%predicted) | 84 (16) | 83 (17) | 83.5 (16.0) | 0.810 |
Disease duration at inclusion (years)f | 1.8 (0.9) | 1.8 (1.2) | 1.8 (1.0) | 0.499 |
Number of visits | 5 (4, 5) | 5 (4, 5) | 5 (4, 5) | 0.964 |
Follow-up time | 3.7 (1.3) | 3.6 (1.0) | 3.7 (1.3) | 0.518 |